Commentary by a child psychiatrist practicing in a community setting

Journal of Child and Adolescent Psychopharmacology

Volumn 17, Issue 3, 2007, Pages 295-299

  Burke, Mary G ^a  

^a Edgewood Center for Children and Families   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID;

BIPOLAR DISORDER; CHILD PSYCHIATRY; CLINICAL PRACTICE; COMMUNITY MENTAL HEALTH; DRUG INDUSTRY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; NOTE; PSYCHIATRIST;

ACADEMIC MEDICAL CENTERS; COMMUNITY MENTAL HEALTH SERVICES; DRUG INDUSTRY; HUMANS; INTERINSTITUTIONAL RELATIONS; PEDIATRICS; PSYCHIATRY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34447515626     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2007.0002     Document Type: Note

References (40)

1. American Academy of Child and Adolescent Psychiatry: Annual report, 2006. Washington, DC: American Academy of Child and Adolescent Psychiatry, 2006.
2. Als-Nielsen B, Chen W, Gluud C, Kjaergard L: Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 290:921-928, 2003.
3. Angell M: The Truth About the Drug Companies: How They Deceive Us and What to Do About It. New York, Random House, 2004.
4. Avorn J: Powerful Medicines: the Benefits, Risks and Costs of Prescription Drugs. New York, Alfred A Knopf, 2004.
5. Barrett P, Healy-Farrell L, March J: Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: A controlled trial. J Am Acad Child Adolesc Psychiatry 42:46-62, 2004.
6. Cicchetti D, Toth S: A developmental psychopathology perspective on child abuse and neglect. J Am Acad Child Adolesc Psychiatry 34:541-565, 1995.
7. Correll C, Carlson H: Endocrine and metabolic effects of psychotropic medications in adolescents. J Am Acad Child Adolesc Psychiatry 45:771-791, 2006.
8. DeAngelis C: The influence of money on medical science. JAMA 296:996-998, 2006.
9. Fava M: Traditional and alternative research designs and methods in clinical and pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 34:1292-1303, 1996.
10. Golden A, Haut S, Moshe S: Nonepileptic uses of antiepileptic drugs in children and adolescents. Pediatr Neurol 34:421-432, 2006.
11. Greenhill L: Introduction - Assessment of safety in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 42:625-626, 2003.
12. Hammen C, Brennan P, Shih J: Family discord and stress predictors and other disorders in adolescent children of depressed and non-depressed mothers. J Am Acad Child Adolesc Psychiatry 43:994-1002, 2004.
13. Healy D: Manufacturing Consensus. Hastings Center Rep 34:end page, 2004.
14. Hunkeler EM, Fireman B, Lee J, Diamond R, Hamilton J, He CX, Dea R, Nowell WB, Hargreaves WA: Trends in use of antidepressants, lithium and anticonvulsants in youth: 1994-2003. J Child Adolesc Psychopharmacol 15:26-37, 2005.
15. Jellinek M: Changes in the practice of child and adolescent psychiatry: Are our children better served? J Am Acad Child Adolesc Psychiatry 38:115-117, 1999.
16. Johnson L: Behavioral drugs for kids on the rise: Spending edges out costs of antibiotics. San Francisco Chronicle May 17, 2004.
17. Kowatch R, Fristad M, Birmaher B, Wagner K, Findling R, Hellander M, the Child Psychiatric Workgroup on Bipolar Disorder: Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 44:213-235, 2005.
18. Kratochvil C, Varley C, Cummins T, Martin A: Less is more: Inpatient management of a child with complex pharmacotherapy. J Am Acad Child Adolesc Psychiatry 54:621-624, 2006.
19. Kravitz R, Epstein R, Feldman M, Franz C, Azari R, Wilkes MS, Hinton L, Franks P: Influence of patient's requests for direct-to-consumer advertised antidepressants: A randomized controlled trial. JAMA 293:1995-2002, 2005.
20. Lieberman A, Ghosh-Ippen C, Van Horn P: Child-parent psychotherapy: 6-month follow-up of a randomized controlled trial. J Am Acad Child Adolesc Psychiatry 45:913-918, 2006.
21. Lyons-Ruth K, Melnick S: Dose-response effect of mother-infant clinical home visiting on aggressive behavior problems in kindergarten. J Am Acad Child Adolesc Psychiatry 43:699-707, 2004.
22. Markel H: Why America needs a strong FDA. JAMA 294:2489-2491, 2005.
23. McClellan J: Commentary: Treatment guidelines for child and adolescent bipolar disorder. J Am Acad Child Adolesc Psychiatry 44:236-239, 2005.
24. McClellan J, Hamilton J: An evidence-based approach to an adolescent with emotional and behavioral dysregulation. J Am Acad Child Adolesc Psychiatry 45:489-493, 2006.
25. McClellan J, Werry J: Evidence-Based treatment in child and adolescent psychiatry: An inventory. J Am Acad Child Adolesc Psych 42:1388-1400, 2003.
26. Office of the N.Y. State Attorney General Eliot Spitzer: 6/18/04, Press Release. Accessed at http://www.oag.state.ny.us/press/2004/jun/jun18a/.
27. Rosack J: Congress hammers FDA over handling of the SSRIs. Psychiatric News 399201:8-10, 2004.
28. Rutter M: Environmentally mediated risks for psychopathology: Research strategies and findings. J Am Acad Child Adolesc Psychiatry 44:3-18, 2005.
29. Safer D: Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis 190:583-592, 2002.
30. Safer D, Zito J, dosReis S: Concomitant psychotropic medication for youths. Am J Psychiatry 160:438-449, 2003.
31. Sameroff A, Emde R: Relationship Disturbances in Early Childhood. New York, Basic Books, 1989.
32. Sierles F, Brodkey A, Cleary L, McCurdy F, Mintz M: Medical students' exposure to and attitudes about drug company interactions: A national survey. 294:1034-1042, 2005.
33. Thomas C, Holzer C: The continuing shortage of child and adolescent psychiatrists. J Am Acad Child Adolesc Psychiatry 45:1023-1031, 2006.
34. U.S. Public Health Service: Report of the Surgeon General's Conference on Children's Mental Health: A national action agenda. Washington, D.C., Department of Health and Human Services, 2000.
35. Vitiello B: Psychopharmacology for young children: Clinical needs and research opportunities. Pediatrics 108:983-989, 2001.
36. Whittington C, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E: Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published vs. unpublished data. Lancet 363:1341-1345, 2004.
37. Wilens T, Biederman J, Kwon A, Chase R, Greenberg L, Mick E, Spencer T: A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. J Child Adolesc Psychopharmacology 13:143-152, 2003.
38. Zipkin D, Steinman M: Interactions between pharmaceutical representatives and doctors in training. J Gen Int Med 20:777-786, 2005.
39. Zito J: A pharmacoepidemiological perspective on ethical issues confronting Child and Adolescent Psychiatrists. AACAP Clinical Panel Presentation, October 25th, 2006.
40. Zito J, Derivan A, Greenhill L: Making research data available: An ethical imperative demonstrated by the SSRI debacle. J Am Acad Child Adolesc Psychiatry 43:512-514, 2004.